GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » 3-Year EBITDA Growth Rate

AXGN (Axogen) 3-Year EBITDA Growth Rate : 13.60% (As of Sep. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Axogen 3-Year EBITDA Growth Rate?

Axogen's EBITDA per Share for the three months ended in Sep. 2024 was $0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 13.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Axogen was 66.40% per year. The lowest was -197.70% per year. And the median was 1.10% per year.


Competitive Comparison of Axogen's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Axogen's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axogen's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axogen's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Axogen's 3-Year EBITDA Growth Rate falls into.



Axogen 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Axogen  (NAS:AXGN) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Axogen 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Axogen's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Axogen Business Description

Traded in Other Exchanges
Address
13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Executives
Angelo Scopelianos officer: Chief R&D Officer C/O AXOGEN, INC., 13631 PROGRESS BOULEVARD - SUITE 400, ALACHUA FL 32615
Karen L. Zaderej director, officer: CEO AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Erick Wayne Devinney officer: VP, Clinical&Translational Sc 13631 PROGRESS BLVD SUITE 400, ALACHUA FL 32615
Michael Patrick Donovan officer: VP Operations C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Peter J Mariani officer: Chief Financial Officer C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr. director HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Marc A Began officer: EVP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall director 13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Maria D. Martinez officer: Chief Human Resources Officer C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Mark Stephen Gold director 13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876